Supernus Pharmaceuticals
NasdaqGM:SUPN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
WA
Consensus Narrative from 5 Analysts
Anticipated Approval Of SPN-830 Will Expand Future Parkinson's Disease Treatment Options
Key Takeaways Robust growth in Qelbree and anticipated launch of SPN-830 position the company for revenue boosts with strong market penetration and new treatment options. Promising clinical data and financial flexibility enable potential for significant growth in treatments for major depressive disorder and treatment-resistant seizures.
View narrativeUS$42.80
FV
22.8% undervalued intrinsic discount4.14%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
about 1 month ago author updated this narrative